Juliol 2018

Fundació Bancària “la Caixa”
Av. Diagonal, 621 Torre 2, Planta 3
08028 Barcelona

A l’atenció de la Direcció de Programes Internacionals, Àrea Internacional de Fundació Bancària “la Caixa”

Distingits senyors:

A continuació, presentem els resultats del nostre treball en relació al projecte de “Revisió de les aportacions realitzades per part de la Fundació Bancària “la Caixa” a GAVI en el marc de l’Aliança Empresarial per la Vacunació Infantil” tal i com s’especificava a la nostra carta de contractació de desembre 2017.

El treball de revisió s’ha dut a terme sobre els imports de l’any 2017 i d’acord amb els següents procediments definits per la Fundació Bancària “la Caixa”:

- Validació de que la informació remesa a GAVI és precisa.
- Validació de que es realitzen les transferències a GAVI del total de les aportacions rebudes de tercers.
- Validació de la transferència d’un milion d’euros realitzada per Fundació Bancària “la Caixa” en favor de GAVI o en cas que les aportacions realitzades pels diferents agents superin el milion d’euros, validació de la transferència adicional realitzada per Fundació Bancària “la Caixa” en favor de GAVI fins a duplicar el total de les aportacions rebudes.

Les aportacions revisades per l’any 2017 es detallen a continuació:

<table>
<thead>
<tr>
<th>Aportacions a GAVI</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>“la Caixa” Foundation</td>
<td>1.274.340,00 €</td>
</tr>
<tr>
<td>Business Alliance</td>
<td>1.105.019,09 €</td>
</tr>
<tr>
<td>Employees and Microdonations</td>
<td>171.846,45 €</td>
</tr>
<tr>
<td><strong>Total (import en euros)</strong></td>
<td><strong>2.551.205,54 €</strong></td>
</tr>
<tr>
<td><strong>Total (import en dòlars)</strong></td>
<td><strong>2.941.785,00 $</strong></td>
</tr>
</tbody>
</table>

(*) Existeix una diferencia de 2.551.205,54 € entre les donacions rebudes i la donació realitzada per la Fundació Bancària “la Caixa degut a una diferencia en el tipus de canvi aplicat a una de les transferències realitzades.

Com a resultat dels procediments realitzats, els informem que no s’han detetcat incidències.

Aprofito l’ocasió per saludar-los atentament,

Juan Ignacio Marull
Soci

Price Waterhouse Coopers Auditores, S.L., Avenida Diagonal, 640, 08017 Barcelona, España
T: +34 932 532 700 F: +34 934 059 032, www.pwc.com/es
R. M. Madrid, hoja 87.250-1, folio 75, tomo 9-267, libro B.054, sección 3ª. Inscrita en el R.O.A.C. con el número 50242 - CIF: B-79 031 290
The use of total funds channelled through "la Caixa" to Gavi programmes in 2017

Final Report to the “la Caixa” Foundation (for Gavi)

July 2018
Executive Summary

The “la Caixa” Foundation and GAVI partnership is aimed at protecting the lives of the world’s most disadvantaged children, with a specific focus on providing life-saving protection against pneumonia by funding pneumococcal vaccine. In 2017 this partnership has contributed funds to vaccinate 539,362 * children in Mozambique. This corresponds to a 64% increase compared to the 2016 figures.

Thanks to the generosity of the “la Caixa” Foundation, “la Caixa” employees, the Business Alliance for Child Vaccinations, and microdonations from the Spanish public, The Bill and Melinda Gates Foundation have matched your funds to thus double the impact.

“la Caixa” Foundation has channeled $5,883,570* to Gavi in 2017. This corresponds to a 68% increase compared to the 2016 figures.

*total includes funds from the Gavi Matching Fund
TABLE OF CONTENTS

1. Overview of use of “la Caixa” funds in 2017

2. Background information on pneumonia and Mozambique

3. Gavi Matching Fund Report
Overview of the use of 2017 funds
2017 Contribution and Impact

“la Caixa” 2017 Contributions:

• “la Caixa” Foundation: $1,452,972

• Business Alliance: $1,288,675

• Employees and Microdonations: $200,138

Total: $2,941,785**

Impact:

• Approximately 1,874,862 doses* of pneumococcal vaccine were purchased

• Approximately 539,362 children immunized***

Note: All impact calculations are estimates.
*total includes possible indicative number of doses purchased with funds from the Gavi Matching Fund
**All Gavi Matching Fund contributions are recorded in US dollars at the actual exchange rates for the day of cash received. The Business Alliance, Employee Giving and public Microdonations Campaigns funds were not all transferred yet. Thus, this amount is an approximate on value date of 15 April 2018.
*** This number includes the 10% wastage.
Detailed breakdown of La Caixa’s funds for pneumococcal vaccines and impact

<table>
<thead>
<tr>
<th>Use of funds and impact in Mozambique</th>
<th>Total La Caixa</th>
</tr>
</thead>
<tbody>
<tr>
<td>La Caixa Foundation &amp; Employees Microdonations</td>
<td>Business Alliance</td>
</tr>
<tr>
<td>Funds (USD)</td>
<td>$1,452,972</td>
</tr>
<tr>
<td>Doses purchased*</td>
<td>463,005*</td>
</tr>
<tr>
<td>Children immunized</td>
<td>133,198</td>
</tr>
<tr>
<td>Funds (%)</td>
<td>49%</td>
</tr>
</tbody>
</table>

*These numbers include the 10% wastage. Total includes possible indicative number of doses purchased without funds from the Gavi Matching Fund - Only La Caixa’s funds.

Note: All impact calculations are estimates. Adjustments from the preliminary report, as well as an increase in funds disbursed vs. funds received, reflect currency adjustments, interest earned, and fluctuations in the global weighted average cost of vaccines.

The prices shared for each vaccine is the Weighted Average Price. We use the WAP as we have multiple presentations of each vaccine and a mix of the presentations is bought by Gavi programs each year. In this case, the $ 3.14 represents a WAP for PCV based off the 2017 UNICEF price list and weighted in proportion to volumes of each presentation procured the previous year. The 2017 UNICEF price list is here: https://www.unicef.org/supply/files/Product_Menu31July2017.pdf
## Detailed breakdown of funds matched by Bill and Melinda Gates Foundation (Matching Fund)

<table>
<thead>
<tr>
<th>Year</th>
<th>Funding Source</th>
<th>Country</th>
<th>Vaccine</th>
<th>Funds Matched (%)</th>
<th>Funds Matched (USD)</th>
<th>Doses Purchased</th>
<th>Children Immunized</th>
</tr>
</thead>
<tbody>
<tr>
<td>2017</td>
<td>Total La Caixa Investment</td>
<td>Mozambique</td>
<td>Pneumococcal</td>
<td>100%</td>
<td>$5,883,570</td>
<td>1,874,862*</td>
<td>539,362</td>
</tr>
<tr>
<td>2017</td>
<td>La Caixa Foundation</td>
<td>Mozambique</td>
<td>Pneumococcal</td>
<td>100%</td>
<td>$2,905,944</td>
<td>926,010*</td>
<td>226,396</td>
</tr>
<tr>
<td>2017</td>
<td>Employees and Microdonations</td>
<td>Mozambique</td>
<td>Pneumococcal</td>
<td>100%</td>
<td>$400,276</td>
<td>127,552*</td>
<td>36,694</td>
</tr>
<tr>
<td>2017</td>
<td>Business Alliance</td>
<td>Mozambique</td>
<td>Pneumococcal</td>
<td>100%</td>
<td>$2,577,350</td>
<td>821,300*</td>
<td>236,272</td>
</tr>
</tbody>
</table>

*These numbers include the 10% wastage.

Note: All impact calculations are estimates. Adjustments as well as an increase in funds disbursed vs. funds received, reflect currency adjustments, interest earned, and fluctuations in the global weighted average cost of vaccines.

The prices shared for each vaccine is the Weighted Average Price. We use the WAP as we have multiple presentations of each vaccine and a mix of the presentations is bought by Gavi programs each year. In this case, the $ 3.14 represents a WAP for PCV based off the 2017 UNICEF price list and weighted in proportion to volumes of each presentation procured the previous year.

The total contributions for 2017 are $1,488,813

**Business Alliance:** $1,288,675
406 companies - $778,494
1,600 Private Banking donations – $510,181

**Employees and Microdonations:**
$200,138
762 employees
60,315 microdonations
Background information on pneumonia and recipient country
The challenge: pneumonia and pneumococcal vaccine

Streptococcus pneumoniae, commonly known as pneumococcal disease, is the leading cause of pneumonia – the world’s number one killer of children under five years of age. According to UNICEF*, Pneumonia kills approximately 2,400 children every day, with the vast majority of these deaths occurring in developing countries.

The most effective way to prevent these deaths is to ensure that all children have access to safe, affordable vaccines.

To accelerate the development and production of a new generation of pneumococcal vaccines, more targeted at the needs of developing countries and more affordable, GAVI, the World Bank and donors launched the pneumococcal Advance Market Commitment (AMC) in 2009.

GAVI countries rolling out pneumococcal vaccines will potentially avert more than 600,000 future deaths in the 2016 to 2020*.

Country immunisation profile: Mozambique

- Total population (2017): 29,537,849
- Birth cohort (2017): 1,122,799
- Surviving Infants (surviving to 1 year per year, 2017): 1,058,346
- Infant mortality rate (deaths < 1 year per 1000 births, 2015): 57/1000
- Child mortality rate (deaths < 5 years per 1000 births, 2015): 79/1000
- World Bank Index, IDA (2015): 3.48
- Gross Nation Income (per capita US$, 2015): 590
- Co-financing group (2018): Initial self-financing
- No. of districts/territories (2016): 159

Non-vaccine support:
- 11%
- $23,060,355

Vaccine support:
- 89%
- $185,634,834

Total: $208.7 Million
Gavi Matching Fund report

Use of Bill & Melinda Gates Foundation Matching Fund funds corresponding to the contributions channelled through “la Caixa” in 2017
Use of Bill & Melinda Gates Foundation Matching Fund funds corresponding to the contributions channelled through “la Caixa” in 2017

### FINANCIAL STATEMENT ON FUNDS UTILIZATION

#### GATES MATCHING FUNDS FOR LA CAIXA

Details of cash contributions received, cash disbursed for Gavi programmes and undischarged cash balance:

#### Table 1: Cash contributions received as of 15 April 2018

<table>
<thead>
<tr>
<th>Description or reference</th>
<th>Amount of contribution in US$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gates Matching Funds for 2017 Funding from La Caixa <a href="https://www.lacaixa.com/">https://www.lacaixa.com/</a></td>
<td>1,021,937</td>
</tr>
<tr>
<td>Gates Matching Funds for 2017 Funding from La Caixa Business Alliance for Childhood Vaccinations, Employer Donations and/or Public Microlendings Campaign</td>
<td>1,072,345</td>
</tr>
<tr>
<td>Gates Matching Funds for 2017 Funding from La Caixa Business Alliance for Childhood Vaccinations, Employer Donations and/or Public Microlendings Campaign</td>
<td>1,453,825</td>
</tr>
<tr>
<td>Gates Matching Funds for 2017 Funding from La Caixa Business Alliance for Childhood Vaccinations, Employer Donations and/or Public Microlendings Campaign</td>
<td>38,931</td>
</tr>
<tr>
<td>Total cash contributions received as of 15 April 2018</td>
<td>2,541,745</td>
</tr>
</tbody>
</table>

#### Table 2: Cash disbursed for Gavi programmes as of 15 April 2018

<table>
<thead>
<tr>
<th>Programme description</th>
<th>Implementing country</th>
<th>Date of cash disbursed by Gavi</th>
<th>Amount of disbursement in US$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Parasitological Programmes (CTN 2013-8598)</td>
<td>Mozambique</td>
<td>15 August 2015</td>
<td>1,322,759</td>
</tr>
<tr>
<td>Parasitological Programmes (CTN 2013-8501)</td>
<td>Mozambique</td>
<td>04 August 2015</td>
<td>822,543</td>
</tr>
<tr>
<td>Parasitological Programmes (CTN 2014-4979)</td>
<td>Mozambique</td>
<td>03 April 2016</td>
<td>785,442</td>
</tr>
<tr>
<td>Total cash disbursed for Gavi programmes as of 15 April 2018</td>
<td>2,930,744</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Table 3: Undischarged balance as of 15 April 2018

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount in US$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total cash contributions received, see Table 1 above</td>
<td>2,541,745</td>
</tr>
<tr>
<td>Total cash disbursed for Gavi programmes, see Table 2 above</td>
<td>-2,930,744</td>
</tr>
<tr>
<td>Total undischarged balance as of 15 April 2018</td>
<td>-389,000</td>
</tr>
</tbody>
</table>

**Notes:**
1. US$ 1,164,200 of the Parasitological Programme for Mozambique in this CTN was sponsored by the Gates Matching Funds. Of this total, US$ 45,441 was covered by the Matching Funds related to La Caixa’s 2016 funding and was, therefore, reported as spent in relation to this CTN in the previous Financial Statement on Funds Utilization as of 30 April 2017. The remaining US$ 1,118,759 was covered by the Matching Funds related to La Caixa’s 2017 funding and was, therefore, reported as spent in this Financial Statement on Funds Utilization.
Thank You!